Bacillus Patents (Class 424/246.1)
  • Patent number: 10214580
    Abstract: The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: February 26, 2019
    Assignee: I2 PHARMACEUTICALS, INC.
    Inventors: Ramesh Bhatt, Lawrence Horowitz, Li Xu
  • Patent number: 10183069
    Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: January 22, 2019
    Assignee: Altimmune Inc.
    Inventor: De-Chu C. Tang
  • Patent number: 10004768
    Abstract: Provided is a method for treatment of atopic dermatitis and infectious dermatitis with biological spa therapy. The method seeks to cure or alleviate symptoms of atopic dermatitis by bathing in a bathwater containing, as dominant bacteria, not less than 105 Bacillus bacteria per 1 mL of the bathwater.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: June 26, 2018
    Inventor: Kensuke Kubo
  • Patent number: 9932570
    Abstract: Disclosed herein is a peptide substrate that is cleaved specifically by anthrax lethal factor (LF), and assays for detecting the presence of anthrax lethal factor in a sample using the peptide substrate. In some cases, the sample may be obtained from an individual at an early stage of an anthrax infection. Kits that include the peptide substrate and that find use in carrying out the assays are also disclosed.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 3, 2018
    Assignee: List Biological Laboratories, Inc.
    Inventor: Nancy Shine
  • Patent number: 9670548
    Abstract: A method of identifying a subject with increased risk of colorectal cancer includes obtaining a biological sample from the subject, measuring the level of Fusobacterium nucleatum in the biological sample, and comparing the measured level to a control level, wherein an increased measured level compared to the control level is indicative of increased risk of colorectal cancer in the subject.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: June 6, 2017
    Assignee: Case Western Reserve University
    Inventor: Yiping Han
  • Patent number: 9314520
    Abstract: The present invention relates to an adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles and a vaccine composition containing the adjuvant composition, and more particularly to an adjuvant composition containing nanoparticles prepared by ionic bonding between poly-gamma-glutamic acid having ensured safety and chitosan, and a vaccine composition containing the poly-gamma-glutamic acid-chitosan nanoparticles and an antigen. The adjuvant containing the poly-gamma-glutamic acid-chitosan nanoparticles has little or no toxicity and side effects and is added to human or animal vaccines for the prevention and treatment of viral and bacterial infections and cancers to increase the production of antibodies.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: April 19, 2016
    Assignees: BIOLEADERS CORPORATION, KOOKMIN UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, THE INDUSTRY AND ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY, CHUNGBUK NATIONAL UNIVERSITY INDUSTRY ACADEMIC COOPERATION
    Inventors: Moon-Hee Sung, Haryoung Poo, Chul Joong Kim, Young-Ki Choi, Yong Taik Lim, Dong Jin Jeong, Sang-Mu Shim
  • Patent number: 9046520
    Abstract: Regions of Bacillus anthracis protective antigen are provided representing epitopes recognized by antibodies in subjects that have acquired immunity to Bacillus anthracis infection. The recognition of these epitopes correlates with autoimmunity in a subject. Also provided are vaccines that include at least one of these epitopes that when administered to a subject provide improved acquired immunity.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: June 2, 2015
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Vera A. Semenova, Conrad P. Quinn, Jan Pohl, Pavel Svoboda
  • Publication number: 20150093412
    Abstract: Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutyrate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutyrate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, National Research Council of Canada
    Inventors: Joanna Kubler-Kielb, Evguenii Vinogradov, Rachel Schneerson, Haijing Hu, Stephen H. Leppla, John B. Robbins
  • Publication number: 20150079133
    Abstract: A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another embodiment of the invention, a method of preventing a disease is provided, comprising insertion into the skin of a patient an array of microprojections comprising a layer which comprises a vaccine for that disease and a polymer.
    Type: Application
    Filed: November 20, 2014
    Publication date: March 19, 2015
    Inventors: Esi Ghartey-Tagoe, Janet Wendorf, Steve Williams, Parminder Singh, Robert Wade Worsham, Joseph C. Trautman, Danir Bayramov, Danny Lee Bowers, Andrew Richard Klemm, Steven Richard Klemm, Guohua Chen
  • Patent number: 8961975
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: February 24, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
  • Patent number: 8916687
    Abstract: The invention relates to an insecticidal protein, its gene encoding and the uses thereof. The protein comprises: (a) a protein consisting of an amino acid sequence shown by SEQ ID NO:2; or (b) a protein derived from (a) consisting of an amino acid sequence by substitution, deletion, or addition of one or more amino acid residues of the amino acid sequences in (a), and having insecticidal activity; or (c) a protein generated by the expression of nucleic acid molecules containing a nucleotide sequence of SEQ ID NO:1; or (d) a protein generated by the expression of nucleic acid molecules containing a complementary sequence that hybridized with SEQ ID NO:1 under stringent conditions; or (e) a protein generated by the expression of nucleic acid molecules that contain nucleotide sequences isocoding with the nucleotide sequences in (d). The insecticidal protein of the invention has high expression level and strong toxicity against pests.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: December 23, 2014
    Assignees: Beijing Green Agrosino Plant Protection Technology Co., Ltd., Beijing Dabeinong Technology Group Co., Ltd., Biotech Center, Beijing Dabeinong Technology Group Co., Ltd.
    Inventors: Aihong Zhang, Jie Pang, Ruiqi Niu, Lihong Niu, Na Wang, Jincun Huang, Yujie Qi
  • Patent number: 8916688
    Abstract: The invention relates to an insecticidal protein, its gene encoding and the uses thereof. The protein comprises: (a) a protein consisting of an amino acid sequence shown by SEQ ID NO:2 or a sequence of amino acid residuses at positions 1 to 640 thereof; or (b) a protein derived from (a) by substitution, deletion, or addition of one or more amino acid residuses of the amino acid sequences in (a), and having insecticidal activity; or (c) a protein generated by the expression of nucleic acid molecules containing a sequence of amino acid residuses at the positions 1 to 1920 of SEQ ID NO:1; or (d) a protein generated by the expression of nucleic acid molecules containing a complementary sequence that hybridized with the sequence of nucleotides at the positions 1 to 1920 of SEQ ID NO:1 under stringent conditions. The protein has high expression level and strong toxicity against pests.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: December 23, 2014
    Assignees: Beijing Green Agrosino Plant Protection Technology Co., Ltd., Beijing Dabeinong Technology Group Co., Ltd., Biotech Center, Beijing Dabeinong Technology Group Co., Ltd.
    Inventors: Aihong Zhang, Jie Pang, Ruiqi Niu, Lihong Niu, Chao Gao, Mengmeng Miao, Donghai Yang
  • Patent number: 8911749
    Abstract: A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another embodiment of the invention, a method of preventing a disease is provided, comprising insertion into the skin of a patient an array of microprojections comprising a layer which comprises a vaccine for that disease and a polymer.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: December 16, 2014
    Assignee: Corium International, Inc.
    Inventors: Esi Ghartey-Tagoe, Janet Wendorf, Steve Williams, Parminder Singh, Robert Wade Worsham, Joseph C. Trautman, Danir Bayramov, Danny Lee Bowers, Andy Klemm, Steven Richard Klemm, Guohua Chen
  • Patent number: 8906630
    Abstract: The present invention encompasses methods, assays and kits for the detection of pathogenic bacteria in a patient and for the differential diagnosis of pulmonary diseases associated with pathogenic bacteria from pulmonary diseases not associated with pathogenic bacteria.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: December 9, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jeffrey N. Weiser, Jane M. Gould
  • Patent number: 8877208
    Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods of inducing an immune response against one or a plurality of pathogens (e.g., vaccinia virus, H5N1 influenza virus, Bacillus anthracis, C. botulinum, Y. pestis, Hepatitis B, and/or HIV, etc.) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., immunogenic composition comprising nanoemulsion and one or a plurality of pathogens (e.g., inactivated by the nanoemulsion) and/or pathogen products and/or pathogen components). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: November 4, 2014
    Assignee: The Regents of the University of Michigan
    Inventors: James R. Baker, Jr., Paul E. Makidon, Nicholas J. Mank, Anna U. Bielinska, Luz P. Blanco, Jessica Knowlton
  • Patent number: 8877483
    Abstract: An accelerating agent for elimination of dioxins which comprises, as an active ingredient, a microorganism having an activity of accelerating elimination of dioxins in the body to the outside of the body.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: November 4, 2014
    Assignee: Calpis Co., Ltd.
    Inventors: Tadashi Shinoda, Akihiro Masuyama, Hidetoshi Morita, Hiroshi Yoshikawa
  • Patent number: 8865428
    Abstract: Disclosed are a highly efficient method for production of heterologous proteins performed by utilizing microorganisms, as well as fusion proteins, and an antiserum. The method includes a method for production of a protein (A) in the form of a fusion protein, comprising the steps of (a) preparing a DNA which codes for a fusion protein comprising the peptide chain forming the protein (A) and the C-terminal peptide or its fragment (B) of the Cry proteins produced by Bacillus thuringiensis, and (b) introducing the DNA into a host bacterium to transform the same, and (c) allowing the fusion protein to be expressed in the transformed host bacterium, as well as a method for production of the protein (A) itself comprising a further step of removing the peptide chain (B) from the fusion protein obtained.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: October 21, 2014
    Assignees: National University Corporation Okayama University, Japan Lamb Co., Ltd.
    Inventors: Hiroshi Sakai, Toru Hayakawa
  • Publication number: 20140302120
    Abstract: The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.
    Type: Application
    Filed: June 19, 2014
    Publication date: October 9, 2014
    Inventors: Dennis A. Carson, Howard B. Cottam, Wolfgang Wrasidlo, Christina C.N. Wu, Gregory A. Daniels
  • Publication number: 20140294895
    Abstract: Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilizes antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against Bacillus anthracis, as well as Yersina pestis. The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to monocot and dicot plants.
    Type: Application
    Filed: March 31, 2014
    Publication date: October 2, 2014
    Applicant: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: Henry Daniell
  • Publication number: 20140294894
    Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 2, 2014
    Applicant: Alba Therapeutics Corporation
    Inventors: Dorothea Sesardic, Blake Paterson
  • Publication number: 20140234404
    Abstract: The invention provides compositions comprising liposomes, an antigen capable of inducing a humoral immune response, a carrier comprising a continuous phase of a hydrophobic substance, and an adjuvant that activates or increases the activity of TLR2. The invention also provides uses for such compositions in inducing a humoral response and methods for their use in the treatment of a disease, disorder or ailment ameliorated by a humoral immune response.
    Type: Application
    Filed: October 5, 2012
    Publication date: August 21, 2014
    Inventors: Marc Mansour, Lisa Diana MacDonald, Genevieve Mary Weir, Leeladhar Sammatur, Kendall Sharp
  • Patent number: 8778359
    Abstract: Formulations of anthrax protective antigen are provided that are stable in storage for prolonged periods. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against anthrax infection.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: July 15, 2014
    Assignee: Emergent BioSolutions Inc.
    Inventor: Elizabet Kaisheva
  • Patent number: 8771708
    Abstract: Cysteine-specific radiolabeled Cry1Fa protein retains insecticidal activity against insect pests and binds to insect brush border membrane vesicle receptors in a saturable manner. The biologically-active radiolabeled Cry1Fa protein is useful in competitive binding assays with other Cry toxins.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: July 8, 2014
    Assignee: Dow AgroSciences LLC
    Inventors: Steven L. Evans, Jianquan Li, Joel J. Sheets
  • Publication number: 20140186399
    Abstract: The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.
    Type: Application
    Filed: December 27, 2013
    Publication date: July 3, 2014
    Applicant: President and Fellows of Harvard College
    Inventor: John J. MEKALANOS
  • Publication number: 20140170188
    Abstract: The invention provides an isolated Bacillus cereus sensu lato strain, selected from Bacillus anthracis, Bacillus cereus and Bacillus thuringiensis, in which the htrA gene or any part thereof is silenced, and vaccines comprising the same.
    Type: Application
    Filed: July 18, 2012
    Publication date: June 19, 2014
    Applicant: STATE OF ISRAEL PRIME MINISTER'S OFFICE ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH
    Inventors: Ofer Cohen, Theodor Chitlaru, Avigdor Shafferman
  • Patent number: 8753635
    Abstract: The characterization and isolation of F20G75, F20G76 and F20G77, anti-PA monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having a Bacillus anthracis infection. The monoclonal antibodies bind to a specific region comprising amino acids 311-316 of PA, ASFFDI or a larger fragment comprising amino acids 301-330 of PA, SEVHGNAEVHASFFDIGSSVSAGFSNSNSS. Vaccines comprising these peptides may be used to immunize individuals against Bacillus anthracis infection.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: June 17, 2014
    Inventors: Raymond Tsang, Jody Berry, Xin Yuan, Cindi Corbett, Mike Gubbins, Amin Kabani, Lisa Schmidt
  • Patent number: 8748173
    Abstract: The present invention provides monoclonal antibodies which are highly specific for Bacillus spores. Also provided are peptides derived from those monoclonal antibodies. Both the antibodies and peptides are highly specific and can discriminate between spores of potentially lethal organisms such as Bacillus anthracis and other harmless but closely related bacilli and provide a very powerful tool in the construction of detection instruments as counter measures.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: June 10, 2014
    Assignee: UAB Research Foundation
    Inventor: John F. Kearney
  • Publication number: 20140141041
    Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).
    Type: Application
    Filed: December 30, 2013
    Publication date: May 22, 2014
    Applicant: VAXIN INC.
    Inventor: De-Chu C. Tang
  • Patent number: 8728491
    Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: May 20, 2014
    Assignee: Alba Therapeutics Corporation
    Inventors: Dorothea Sesardic, Blake Paterson
  • Publication number: 20140112951
    Abstract: Disclosed and claimed is a method of non-invasive immunization in an animal and/or a method of inducing a systemic immune response or systemic therapeutic response to a gene product. The skin of the animal is contacted with a non-replicative vector chosen from the group of bacterium, virus, and fungus, wherein the vector comprises and expresses a nucleic acid molecule encoding the gene product, in an amount effective to induce the response.
    Type: Application
    Filed: August 7, 2013
    Publication date: April 24, 2014
    Applicant: UAB RESEARCH FOUNDATION
    Inventors: De-Chu C. Tang, Zhongkai Shi, Kent Rigby van Kampen
  • Patent number: 8703150
    Abstract: The invention relates to improved methods of producing and recovering B. anthracis protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, B. anthracis bacterial infections and which are useful to prevent and/or treat illnesses caused by B. anthracis, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: April 22, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen H. Leppla, Rachel Schneerson, John B. Robbins
  • Patent number: 8697049
    Abstract: Provided is a modified bacteriophage capable of infecting a target bacterium, which bacteriophage includes an ?/? small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacterium, wherein the SASP gene is under the control of a constitutive promoter which is foreign to the bacteriophage and the SASP gene.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: April 15, 2014
    Assignee: Phico Therapeutics Ltd.
    Inventors: Heather Fairhead, Adam Wilkinson, Sarah Holme, Katy Pitts, Alison Jackson
  • Patent number: 8685721
    Abstract: A surface expression vector for preparing HPV immunogenic compositions, in which the surface expression vector contains a gene encoding a repE mutant protein having an amino acid sequence of SEQ ID NO: 1, a promoter, a poly-gamma-glutamate synthetase complex gene, and a gene which is linked with the poly-gamma-glutamate synthetase complex gene and encodes a tumor induction-associated antigen protein of human papillomavirus. An expression vector constitutively expressing a high level of the human papillomavirus (HPV) antigen protein is provided. Also, a recombinant lactic acid bacteria, transformed with the expression vector and expressing the HPV antigen protein on the surface thereof, and a composition comprising the recombinant lactic acid bacteria are provided. The recombinant lactic acid bacteria and the composition are very effective as a immunogenic composition for the treatment of cervical cancer, because they can be applied orally or directly to the vagina.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: April 1, 2014
    Assignees: Bioleaders Corporation, Kookmin University Industry-Academy Cooperation Foundation
    Inventors: Moon-Hee Sung, Haryoung Poo, Il Han Lee
  • Publication number: 20140086989
    Abstract: The present invention relates to immunogenic compositions containing one or more antigens of interest, one or more carrier proteins, and one or more polycations, wherein the antigen of interest is entrapped with cross-linked carrier protein matrix and one or more polycations, methods of making such vaccines, and methods of vaccine administration.
    Type: Application
    Filed: May 15, 2012
    Publication date: March 27, 2014
    Applicant: Matrivax, Inc.
    Inventors: Kevin P. Killeen, Robert T. Cartee
  • Patent number: 8673311
    Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: March 18, 2014
    Assignee: Royal Holloway and Bedford New College
    Inventors: Simon Michael Cutting, Hong Anh Huynh
  • Patent number: 8663926
    Abstract: One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, a patient may be days beyond the time when treatment would be effective by the time a diagnosis is made. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax lethal factor activity exhibited by the instant invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines and lethal factor inhibitors. The instant invention isolates and concentrates lethal factor and lethal toxin from nearly any biological sample.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: March 4, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Anne E. Boyer, Conrad P. Quinn, John R. Barr
  • Publication number: 20140056958
    Abstract: The present invention creates a biologically protected or enhanced space in vivo in a mammal to allow the mammal's immune system and/or other biological processes to function properly in order to treat autoimmune diseases. In particular, the biologically protected/enhanced space allows biological processes to occur that can therapeutically treat Type I diabetes. The biologically enhanced/protected space can also be used to promote growth of specific cells such as insulin producing islet cells of the pancreas. Microfluidic devices can also be used to remove soluble TNF receptors and autoreactive T Cells in treating autoimmune diseases. Additionally, microfluidic devices can be used to remove blood glucose, soluble insulin receptors and insulin-like growth factor (IGF) from blood in the treatment of adult onset (Type II) diabetes.
    Type: Application
    Filed: March 5, 2012
    Publication date: February 27, 2014
    Inventors: Charles Knezevich, Robert D. Silvetz
  • Publication number: 20140056908
    Abstract: The present invention relates to novel nucleic acid molecules for producing target polypeptides in plant cells. More specifically, the novel nucleic acid molecules comprise a minireplicon derived from a Closteroviridae virus and heterologous polynucleotides encoding the target polypeptides. Also provided are compositions comprising the target polypeptides and uses thereof.
    Type: Application
    Filed: October 7, 2011
    Publication date: February 27, 2014
    Applicant: FRAUNHOFER USA INC.
    Inventors: Alexei Prokhnevsky, Vidadi Yusibov, Vadim Mett
  • Publication number: 20140050764
    Abstract: The invention relates to the use of lactic acid-producing bacteria to boost the immune system.
    Type: Application
    Filed: October 28, 2013
    Publication date: February 20, 2014
    Applicant: Ganeden Biotech, Inc.
    Inventors: Sean Farmer, Michael A. Bush, David Keller
  • Publication number: 20140037716
    Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.
    Type: Application
    Filed: March 19, 2012
    Publication date: February 6, 2014
    Inventor: Alexandre Eduardo Nowill
  • Publication number: 20140004150
    Abstract: The invention provides a vaccine injection, which includes a vaccine and a Traditional Chinese medicinal adjuvant in a mass ratio of 1:0.5-1:10, or a vaccine, a Traditional Chinese medicinal adjuvant and an aluminum adjuvant in a mass ratio of 1:0.5:2.5-1:10:20. The vaccine injection is in the form of powders, and the size of the powders is between 10 and 120 micrometers. The vaccine injection of the present invention is particularly suitable for the needle free injection technology. The invention also provides a preparation method for the vaccine injection.
    Type: Application
    Filed: April 8, 2011
    Publication date: January 2, 2014
    Applicants: CHINA 302 MILITARY HOSPITAL OF PLA
    Inventors: Jiabo Wang, Xiaohe Xiao, Zhewei Wang, Cheng Jin, Qi Li
  • Patent number: 8574853
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: November 5, 2013
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
  • Publication number: 20130273097
    Abstract: Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.
    Type: Application
    Filed: June 4, 2013
    Publication date: October 17, 2013
    Inventors: Joanna Kubler-Kielb, Evguenii Vinogradov, Rachel Schneerson, Haijing Hu, Stephen H. Leppla, John B. Robbins
  • Publication number: 20130273101
    Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 17, 2011
    Publication date: October 17, 2013
    Applicant: EYEGENE, INC.
    Inventors: Yang Je Cho, Na Gyong Lee, Jin Wook Jang, Kwang Sung Kim, Won Il Yoo
  • Patent number: 8551498
    Abstract: The invention relates to a composition of spores of nonpathogenic bacteria of the Bacillus genus, adsorbed onto a matrix made up of at least one water-insoluble adsorbent compound and a cellulose derivative, which can be obtained by the fluidized air bed technique, useful in the pharmaceutical, veterinary and nutrition fields.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: October 8, 2013
    Assignee: Sanofi-Aventis S.p.A.
    Inventor: Tiziano Prato
  • Patent number: 8524223
    Abstract: A microorganism inhibits the growth of various plant pathogens, and is not reduced in its efficacy even when the microorganism is used in combination with a chemical pesticide. The microorganism is Bacillus subtilis KS1 strain (NITE BP-569). The plant disease control agent comprises a culture of the microorganism as an active ingredient.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: September 3, 2013
    Assignee: University of Yamanashi
    Inventors: Tsutomu Takayanagi, Shunji Suzuki, Seiichi Furuya
  • Publication number: 20130216577
    Abstract: The present invention describes the use of lactic acid bacteria, particularly lactic acid producing members of the genus Bacillus, in treating digestive-related immune disorders by downregulating of cytokines and by inhibiting pathogenic or deleterious microorganisms in the gastrointestinal tract. Specific formulations of Bacillus coagulans for various immune disorders are elaborated.
    Type: Application
    Filed: March 20, 2013
    Publication date: August 22, 2013
    Inventor: Ganeden Biotech, Inc.
  • Publication number: 20130189308
    Abstract: Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilizes antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against Bacillus anthracis, as well as Yersina pestis. The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to monocot and dicot plants.
    Type: Application
    Filed: November 26, 2012
    Publication date: July 25, 2013
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventor: Henry Daniell
  • Patent number: 8492519
    Abstract: The present invention relates to a modified polypeptide with a biological activity to lyse cell walls of bacteria, wherein the polypeptide has no caspase, clostripain, enterokinase, factor Xa, granzyme B, staphylococcus peptidase I (V8 Protease), plasmin, streptopain, bacillolysin and/or thrombin cleavage site. The invention further relates to nucleic acids with a sequence encoding a polypeptide according to the present invention.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: July 23, 2013
    Assignees: Hyglos Invest GmbH, bioMérieux S.A.
    Inventors: Holger Grallert, Michael Forchheim
  • Publication number: 20130183345
    Abstract: Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis and treatment; particularly, determining the expression levels of protective markers (COL4A3BP, MBNL2, FABP4, NEK1 and SKAP2) and harmful markers (COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B) and making treatment decisions in consideration of increased or decreased risk of progression based on the marker expression levels.
    Type: Application
    Filed: March 8, 2013
    Publication date: July 18, 2013
    Applicants: CATALYST ASSETS, LLC
    Inventors: Lars Dyrskjøt Andersen, Torben Falck Orntoft, Joseph A. Sorge, Alexey Novoradovsky